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Children with idiopathic short stature (ISS) are statistically defined by height SDS < −2 for their bone age and should be
distinguished from children with familial short stature for whom height SDS corresponds to mean parental SDS and from the
most common explanation for short stature referred to pediatric endocrinologists, constitutional delay in growth and maturation
(CDGM), in which there is normal height for bone age and predicted normal adult stature. Low IGF-I levels reported in ISS
may be the result of subtle undernutrition or reference to standards appropriate for chronologic age but not osseous maturation
in CDGM inappropriately labeled as ISS. While growth hormone (GH) treatment of ISS may add 4-5 cm to adult height, meta-
analysis indicates that there is no documented evidence that such treatment improves health related quality of life or psychological
adaptation. Thus, the estimated cost of US$52 000/inch gained is diﬃcult to justify. Absence of data regarding eﬃcacy of the use
of IGF-I for treatment of ISS has been noted in a recent consensus statement from the North American and European pediatric
endocrinology societies. This report further emphasizes the importance of discouraging the expectation that taller stature from
GH treatment will improve quality of life.
Copyright © 2009 Arlan L. Rosenbloom. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. What Is Idiopathic Short Stature?
Short stature is often defined statistically as height less than
−2 standard deviations (SD) of the age- and sex-matched
population [1]. Such an arbitrary definition, however, would
be inappropriate for the oﬀspring of taller than normal or
shorter than normal parents; a more appropriate definition
for clinical purposes might be 2 SD below the mean parental
SD score (SDS). Experienced clinicians have seen children
with stunting conditions such as Turner syndrome not
resulting in obvious short stature based on population
because of tall parentage, and short stature meeting the
population definition in children who are perfectly normal
for their families [1]. Because stature in the population is a
Gaussian distribution, some 2% of children will always be
more than 2 SD below the mean for age and sex [2].
The issue is further complicated by wide variation in rates
of maturation, such that a child may be short for age but not
for osseous maturation. The definition of “idiopathic short
stature” (ISS) should be appreciated in this context. The
recent consensus statement on the diagnosis and treatment
of children with idiopathic short stature defines ISS simply
by height >2 SD below the corresponding mean height of
a given age, sex, and population group without evidence
of systemic, endocrine, nutritional, or chromosomal abnor-
malities, and normal stimulated growth hormone (GH)
levels [3]. It was noted that this definition included short
children with constitutional delay in growth and maturation
(CDGM) and those with familial short stature (FSS). While
CDGM, which is often familial, and FSS are in a broad sense
idiopathic, this inclusive classification obscures important
diagnostic and treatment diﬀerences among the 3 entities. A
child with ISS has a height SDS < −2 for his or her osseous
maturation, and for mean parental height SDS. Such a child
has an adult height prediction SDS < −2, and might be
considered a candidate for growth therapy. The child with
FSS will also be short for osseous maturation, as well as age,
but as noted above, the height SDS will correspond to mean
parental SDS. In such families, the short staturemay be of less
concern. The most common explanation for short stature
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in the pediatric endocrinology clinic is CDGM with normal
stature for osseous maturation and normal adult height
prognosis; this obviously dictates very diﬀerent counseling
and treatment consideration than ISS or FSS. Inconsistent
with the classification of CDGM as ISS in the consensus
document, specific treatment recommendations unique to
CDGM were made [3]. These entities may overlap [1].
Subtle nutritional growth retardation, most frequently
described in aﬄuent communities due to self/family imposed
dietary restriction, may be easily missed in the evaluation of
short children [1, 4]. Such marginal undernutrition and its
lack of clinical manifestations or biochemical abnormalities
can explain the shorter stature of earlier generations, and in
those lacking critical micronutrients [5]. Approximately one
half of German children with “ISS” were found to be poor
eaters and to have lower body mass indices than normal [6].
Since the availability of unlimited supplies of recom-
binant human (rh) GH beginning in 1985, the definition
of GHD has been greatly liberalized and has led to the
inclusion and rhGH treatment of countless numbers of
normal short children. This reflects the uncertainties of
GH testing for the exclusion of GHD in children with ISS,
FSS, or CDGM, including: assay variability; intraindividual
variability; the arbitrary definition of normal; the influence
of age, sex, pubertal status, and BMI on response; and
deficient responses in the absence of endocrine disease (e.g.,
with undernutrition) and during the preadolescent growth
lag phase. Furthermore, response to GH stimulation testing
correlates with the success of GH treatment only when there
is unequivocal deficiency. The unreliability of GH testing
and the ease with which normal prepubertal children can be
misdiagnosed as having GHD, was demonstrated among 84
normal children, using the relatively conservative criterion
of GH concentration ≥7 ng/mL in response to treadmill
and arginine-insulin stimulation. In those children who
were at Tanner stage (TS) 4-5, 100% met the criterion,
while 89% of those at TS 3 did. Only 44% of TS 1-
2 children, however, reached this criterion, but following
ethinyl estradiol priming, 100% did. Using the commonly
promoted criterion of 10 ng/mL, 94% of TS 4-5, 77% of TS
3, and only 23% of TS 1-2 children “passed.” The obvious
conclusion was that there is little value in GH testing of
children at TS 1-3 unless they are primed with sex steroids
[7]. This phenomenon probably accounts for the fact that
70% of patients treated for isolated GHD in childhood have
normal GH responses when tested after adolescence [8].
The approval of the use of recombinant growth hormone
(rhGH) for the treatment of ISS by the United States Food
and Drug Administration (FDA) used a population-based
definition (height SDS < −2.25) and otherwise highly
interpretable criteria (open epiphyses, growth rate unlikely
to result in normal adult height) that has reinforced the
tendency to include CDGM and FSS under the rubric of ISS.
It is remarkable that the treatment criterion of growth rate
unlikely to result in normal adult height is missing from the
consensus definition of ISS, an absence that allows for the
odd inclusion of CDGM as a category of ISS [3].
FDA approval of the pharmacological (as opposed to
the physiologic replacement in GHD) use of rhGH for a
rather loosely defined ISS has reduced further the traditional
adherence to the sequence of specific diagnosis dictating
therapy. It has been in the marketing interest for rhGH, and
more recently for rhIGF-I, to promote expanded and vague
definitions, or to introduce novel diagnoses [9, 10].
2. Is ISS a Disease?
The medical dictionary defines disease as, “a definite patho-
logical process having a characteristic set of signs and
symptoms. It may aﬀect the whole body or any of its parts,
and its etiology, pathology, and prognosis may be known or
unknown” [11]. In an otherwise healthy child, short stature
can only be considered “a pathological process” if there
is, in fact, pathology justifying removal of the idiopathic
descriptor, or if there are demonstrable handicapping eﬀects.
The 2005 FDA and 2007 European Commission
approvals of rhIGF-I for the treatment of rare GH insen-
sitivity disorders (GH receptor deficiency, GH inactivating
antibodies, defects in the GH activation pathway, and
IGF-I mutations), unfortunately labeled with a novel and
nonspecific diagnosis as “severe primary IGF-I deficiency
(IGFD)” has opened the door for oﬀ-label trials based on
the dubious finding of a single low IGF-I for age [9, 10]. The
promotion of IGF-I for treatment of ISS has focused on lower
IGF-I levels in about half of such patients as an indication
of “primary IGFD.” As with GH testing, however, IGF-I
determinations are unreliable for a variety of reasons: normal
ranges vary; laboratories diﬀer; there is high susceptibility
to post sampling proteolysis; and levels can be low with
undernutrition and ADHD medications, and with CDGM
[12–14]. IGF-I generation tests have not been reliable or
reproducible [3, 15]. Perhaps most importantly, the data
regarding lower circulating IGF-I concentrations in ISS are
highly suspect because the populations studied include a
majority of CDGM who have substantially delayed bone age
and the IGF-I concentrations are interpreted for chronologic
age. One would not expect a delayed 14-year-old boy with 4
cc testes and a bone age of 11 years (a typical presentation)
to have a normal testosterone level for a 14-year-old. Similar
logic should apply to interpreting IGF-I measurement, which
is also developmental level dependent. In this example, an
IGF-I concentration at −2 SD would become −1 SD when
corrected for bone age.
While it may be intuitive that short stature is a handicap
and, therefore, definable as a disease, neither history nor
clinical research support this notion. Among notable literary,
musical, and historical figures between −4 and −2 SDS
are JM Barrie, Immanuel Kant, Jean-Paul Sartre, Edvard
Greig, Napoleon, Voltaire, and Gandhi; others ranging from
−7 to −3.5 SDS are noted in Table 1 [16]. Up until
∼15 years ago, the conventional wisdom was that children
with short stature were at risk for significant academic
and social problems [17]. This view was based on clinical
impressions from referred children and methodologically
inadequate studies. Studies from England were the first to
indirectly demonstrate referral bias, finding that normal
children with short stature have unimpaired self-esteem
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and behavior, and normal IQ, but may underachieve and
this was attributable to the association of shorter stature
with lower socioeconomic status [18]. In a comparable US
study, which included normal statured children as well as
short referred and short nonreferred subjects, no diﬀerences
were found in intelligence or achievement using teacher,
parent, and child measures, but referred children had more
externalizing behavior problems and poorer social skills,
confirming referral bias [19]. Other studies have failed to
show clinically significant psychosocial morbidity, school
achievement or quality of life diﬀerences fromnormal among
children referred for short stature [20–22]. Even among
GHD patients, quality of life was unrelated to adult height
and no diﬀerent than same-sex unaﬀected siblings [23].
3. Should ISS Be Treated?
Commercial eﬀorts attendant on the availability of rhGH
starting in 1985 included various forms of supporting pedi-
atric endocrinology programs, individual endocrinologists,
and patient advocacy groups. The result was broadening of
the definition of GHD and the range of conditions treated
with rhGH, including the moving of many normal short
children into rhGH treatable categories.
4. Recombinant GH
By definition, normal short stature does not require treat-
ment for physical health benefits. Therefore, justification
for growth enhancement therapy requires demonstration
of individual or societal benefits, evidence of eﬃcacy with
absolute safety, and cost-benefit. Treatment of ISS with
rhGH, as might be expected by the lack of definitive
psychosocial problems attendant on short stature per se,
has generally not been shown to aﬀect school achievement,
psychosocial measures, or quality-of-life when rhGH treated
and untreated normal short children are compared [24–27].
Coincident with the absence of demonstrable individual
or societal benefits of rhGH treatment of ISS, there is only
modest evidence for eﬃcacy, as might be expected when
rhGH is being administered to non-GHD individuals [3].
With treatment for a period of ∼5 years, 4-5 cm of added
adult height can be expected, with wide individual variability.
While it may be assumed that higher doses of rhGH, resulting
in IGF-I levels comparable to those associated with growth
promoting GH producing tumors would result in greater
growth promotion, the potential for adverse metabolic and
mitogenic side eﬀects would not justify such an adventure.
A recent meta-analysis of 10 randomized controlled trials
of rhGH therapy in ISS found none of the studies to be
of good quality and only two to be of moderate quality in
terms of randomization methods, blinding, and the handling
of withdrawals [28]. The conclusion from this analysis was
“Although treated individuals may be taller than nontreated
individuals, they are still relatively short compared with peers
of normal height. Therefore, whether the small expected gain in
height is substantial enough to merit frequent or daily injections
for a number of years in children who do not have a disease
is not clear. Additionally, there is no evidence that growth
hormone treatment improves health related quality of life or
psychological adaptation.”
In the absence of evidence for individual or societal
benefit, pharmacologic rhGH therapy for normal short
stature does not appear cost beneficial. Amg of human rhGH
costs ∼1000 times as much as a mg of comparably produced
bovine GH, used for enhancing milk production. It has been
estimated that the average cost of rhGH per inch (2.5 cm)
of height attainment is US $52 000 [29]. Even if the price
were to approximate actual value, there would still be costs
for medical visits, IGF-I monitoring, parental work time lost,
school absence, and injection supplies that would need to be
justified. While failure to meet often unreal expectations and
the eﬀects of medicalizing otherwise healthy children might
be considered a potential risk, recent data suggest stable
psychological functioning in children with ISS receiving
rhGH or placebo [27].
5. Recombinant IGF-I
The issue of pharmacological hormonal therapy for ISS
has become further complicated by the intense oﬀ label
promotion of rhIGF-I since 2005, based on the conjecture
that most ISS is due to primary IGFD, which requires that
clinicians, “Replace what’s missing.” The manufacturer has
recruited clinicians to promote the egregious estimate of
60 000 aﬀected youngsters in the US and Europe [30] and
to present case histories as indicative of patients who should
receive IGF-I, but which do not meet approved criteria, and
include straightforward CDGM [31]. As noted earlier, it is
likely that the observation of reduced IGF-I concentrations in
ISS is an artifact of erroneous analysis for chronologic rather
than developmental (bone) age, if not a reflection of subtle
undernutrition. The notion that IGF-I is a better growth
promoter in ISS than is GH is without theoretical basis or
clinical evidence over the three years that oﬀ-label use of
rhIGF-I has been promoted. The absence of data regarding
eﬃcacy and safety of the use of IGF-I for treatment of ISS
has been noted in the consensus report [3].
6. Other Treatment Considerations
Oxandrolone, a nonaromatizable synthetic androgen that
can be administered orally, has been extensively studied
in Turner syndrome and CDGM, and to supplement GH
therapy in GHD and Turner syndrome [32]. Despite much
anecdotal experience, there are no published data on its use
in ISS. At low dosage (≤0.1mg/kg/day) undue acceleration
of osseous maturation with compromise of adult height
does not occur; thus, consideration for ISS is not irrational.
Aromatase inhibition, resulting in the interruption of the
conversion of androgens to estrogen can delay osseous
maturation, permitting a prolonged preadolescent growth
period. Increased predicted adult height has been noted in
boys with CDGM treated with aromatase inhibitor [33] and
in boys with GHD treated with both rhGH and aromatase
inhibition [34]. There are no data for ISS.
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Table 1: Short stature does not impede achievement.
Name Height Accomplishments
CP Steinmetz 4′ (122 cm) Electrical engineer whose ideas on alternating current systems helped inaugurate the electrical era
in the US
Chick Web 4′ (122) Prominent bandleader and jazz drummer of the swing era
Michael Ain 4′3′′ (130) Orthopedic surgeon-Johns Hopkins
Benito Juarez 4′6′′ (137) National hero and president of Mexico from 1861 to 1863 and 1867 to 1872
Robert B. Reich 4′9′′ (147) Professor of social and economic policy at Brandeis University. Secretary of labor in Pres.
Clinton’s first term from 1993–1997
Andrew Carnegie 5′ (152) Phenomenally successful entrepreneur- virtual founder of American steel industry and
philanthropist (Carnegie Mellon University, Carnegie Hall, libraries throughout US)
David Ben Gurion 5′ (152) Founding Zionist and first prime minister of Israel
Thomas Hart Benton 5′ (152) One of the foremost painters and muralists in 20th Century America
7. Conclusion
ISS is a diagnosis of exclusion and for clinical and counseling
purposes needs to be considered distinct from CDGM and
FSS. The most frequent reason for referral to pediatric
endocrinologists, after diabetes management, is for evalu-
ation and treatment of short stature. Most such children,
who are predominately boys, have CDGM with height age
comparable to bone age, indicating a normal adult height
prognosis [35]. Such individuals, if they require treatment,
can be given a three-month course of testosterone to
accelerate adolescence without compromising final height,
or a longer course of oxandrolone [3]. There is no rationale
for treating this normal variation with rhGH on the basis
of GH stimulation testing without sex steroid priming, and
certainly not with rhIGF-I. FSS and ISS are characterized
by deviant height for bone age and likelihood of adult
short stature, which can be modestly, at best, altered by
pharmacologic and costly rhGH treatment. There is no
scientific rationale or evidence basis to suggest that rhIGF-
I would be more eﬀective than rhGH in promoting growth
in children with ISS, and reason to suspect that it might be
counterproductive, suppressing endogenous GH eﬀects on
growing bone [9, 36]. The recent consensus statement from
the North American and European pediatric endocrinology
societies notes the absence of evidence for psychosocial
impact of short stature and the importance of discouraging
the expectation that taller stature will improve quality of
life [3].
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